Can a pill make CAR T-Cells last longer?
NCT ID NCT05044039
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether the drug duvelisib can help CAR T-cells persist longer in people with non-Hodgkin lymphoma or acute lymphocytic leukemia. About 42 adults who have already received a standard CAR T-cell therapy will take duvelisib pills daily. The main goal is to check safety and see if it reduces side effects like cytokine release syndrome.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Duvelisib (a PI3K inhibitor pill)
What this could lead to
If it works, this could help CAR T-cells last longer in the body and reduce serious side effects like cytokine release syndrome.
What could go wrong
This is an early phase 1 trial with only 42 participants, so safety and effectiveness are not yet proven. Duvelisib may cause its own side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States